(MENAFN - ProactiveInvestors - Australia) Antisense Therapeutics (ASX: ANP) has been placed in pre-open this morning following the ASX granting the company a trading halt, pending the release of details regarding the FDA approval of KYNAMRO.
KYNAMRO is a first-in-class apo-B synthesis inhibitor currently under regulatory review for patients with homozygous familial hypercholesterolaemia (HoFH) to further reduce LDL cholesterol (LDL-C) in patients already maintaining a stable regimen of maximally-tolerated lipid-lowering therapies, and who require additional significant lipid-lowering therapy.
It is intended to reduce LDL-C by preventing the formation of atherogenic lipoproteins, the particles that carry cholesterol through the bloodstream.
KYNAMRO acts by blocking the production of apolipoprotein B (apo B), the protein that provides the structural core for these atherogenic particles, including LDL and lipoprotein-a (Lp(a)).
The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Friday 1st February.